News
Kathryn Kinch, senior pharma product manager at GlobalData, said, “Increased approvals of biosimilars are likely to lower biologic prices, enhancing consumer demand and competition among drug ...
While biosimilar drugs promise greater affordability and accessibility for millions with chronic diseases, can this momentum of bringing biosimilars to the market persist despite the rising costs ...
Sandoz has signed a global collaboration agreement with Shanghai Henlius Biotech to commercialize a biosimilar of oncology therapy, ipilimumab (Bristol-Myers Squibb’s Yervoy). The agreement is ...
For instance, 90% of all medicines prescribed in the U.S. are not branded drugs. They are generics and biosimilars. The vast majority of generic medicines in the U.S. cost $20 or less; average ...
Hosted on MSN29d
Best Gantt chart software: Pros, cons, and costsBest Gantt chart software: A closer look at our top picks Asana Best for: Full-suite work management Why we picked it: Asana offers more than just Gantt charts; it’s full-suite work management ...
In the past month, President Trump signed two executive orders concerning drug access and affordability, including for biologics and biosimilar drugs. On April 15, 2025, President Trump signed ...
Understanding what sets IL-23 inhibitors apart in the IBD management paradigm may hold clues to where each biologic and biosimilar product ... for marketed drugs that have lost patent protection.” ...
biosimilars growth, and expansion in the US market. Excerpts: Q How does President Trump’s executive order on reducing the cost of prescription drugs in the US impact Indian pharmaceutical ...
Kiran Mazumdar Shaw, chairperson, Biocon Group, said, “This order does not target generics and biosimilars, which already provides affordable alternatives under the Affordable Care Act (ACA). It does ...
Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...
Editor’s note: “Behind the News“ is the product of Sun staff assisted by the Sun’s AI lab, which includes a variety of tools such as Anthropic’s Claude, Perplexity AI, Google Gemini and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results